Bactroban Ointment

  • Name:

    Bactroban Ointment

  • Company:
    info
  • Active Ingredients:

    Mupirocin

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 19/03/19

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 27/8/2015
print

Print ViewKeyword Search SmPC

GlaxoSmithKline (Ireland) Ltd

GlaxoSmithKline (Ireland) Ltd

Company Products

Medicine NameActive Ingredients
Medicine Name Amoxil Paediatric Suspension Active Ingredients Amoxicillin trihydrate
Medicine Name Amoxil Vial for Injection 500mg Active Ingredients Amoxicillin sodium
Medicine Name ANORO ELLIPTA 55 micrograms/22 micrograms inhalation powder, pre-dispensed Active Ingredients Umeclidinium bromide, Vilanterol trifenatate
Medicine Name Augmentin 250 mg/125 mg film-coated tablets Active Ingredients Amoxicillin trihydrate, Potassium clavulanate
Medicine Name Augmentin 500mg/125mg Film-coated Tablets Active Ingredients Amoxicillin trihydrate, Potassium clavulanate
Medicine Name Augmentin 875/125mg Film Coated tablets Active Ingredients Amoxicillin trihydrate, Clavulanic Acid
Medicine Name Augmentin Duo Mixed Fruit 400 mg/57 mg /5 ml Powder for Oral Suspension Active Ingredients Amoxicillin trihydrate, Clavulanic Acid
Medicine Name Augmentin DUO Suspension 400/57mg Active Ingredients Amoxicillin trihydrate, Potassium clavulanate
Medicine Name Augmentin Intravenous 1.2g Active Ingredients Amoxicillin sodium, Potassium clavulanate
Medicine Name Augmentin Paediatric 125mg/31.25mg per 5ml Powder for Oral Suspension Active Ingredients Amoxicillin trihydrate, Potassium clavulanate
Medicine Name AVAMYS 27.5 micrograms/spray nasal spray suspension Active Ingredients Fluticasone furoate
Medicine Name Avodart Soft Capsules 0.5mg Active Ingredients Dutasteride
Medicine Name Babyhaler Active Ingredients No Active Ingredients
Medicine Name Bactroban Nasal Ointment Active Ingredients Mupirocin calcium
Medicine Name Bactroban Ointment Active Ingredients Mupirocin
Medicine Name Becotide Evohaler 100 Active Ingredients Beclometasone Dipropionate
Medicine Name Becotide Evohaler 250 Active Ingredients Beclometasone Dipropionate
Medicine Name Becotide Evohaler 50 Active Ingredients Beclometasone Dipropionate
Medicine Name Benlysta 120 mg and 400 mg powder for concentrate for solution for infusion Active Ingredients Belimumab
Medicine Name Betnovate C 0.1% / 3% w/w Cream Active Ingredients Betamethasone Valerate, Clioquinol
Medicine Name Betnovate Cream 0.1% w/w Active Ingredients Betamethasone Valerate
Medicine Name Betnovate Ointment 0.1% w/w Active Ingredients Betamethasone Valerate
Medicine Name Betnovate RD Cream Active Ingredients Betamethasone Valerate
Medicine Name Betnovate RD Ointment Active Ingredients Betamethasone Valerate
Medicine Name Betnovate Scalp Application 0.1% w/v Cutaneous Solution Active Ingredients Betamethasone Valerate
1 - 0 of 136 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 19 March 2019 PIL

Reasons for updating

  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision

Updated on 27 August 2015 PIL

Reasons for updating

  • New PIL for new product

Updated on 27 August 2015 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 27 August 2015 SmPC

Reasons for updating

  • Change to section 10 - Date of revision of the text
  • Change to section 2 - Qualitative and quantitative composition

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 2 – active substance correction
Section 10 – date of revision updated

Updated on 27 August 2015 PIL

Reasons for updating

  • Change of trade or active ingredient name
  • Change to date of revision

Updated on 17 July 2015 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Change to address of the MA Holder

Updated on 17 July 2015 PIL

Reasons for updating

  • Change to date of revision
  • Change to MA holder contact details

Updated on 2 July 2015 PIL

Reasons for updating

  • Change of trade or active ingredient name
  • Change to, or new use for medicine
  • Change to storage instructions
  • Change to side-effects
  • Change to drug interactions
  • Change to date of revision
  • Addition of information on reporting a side effect.
  • Correction of spelling/typing errors

Updated on 2 July 2015 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.3 - Shelf life
  • Change to section 6.5 - Nature and contents of container
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company



·         Section 2 – Update to qualitative and quantitative composition statement

·         Section 3 – Editorial update

·         Section 4.2 – Minor QRD update

 

·         Section 4.4 - Editorial updates and re-structuring to keep the renal impairment issues together with a consequential update to section 5.2. The reposition of the warning statements is amended as follows:

- Text relating to polyethylene glycol absorption has been moved directly below the “Renal impairment” title.

- Statement regarding elderly patients has been removed from the section 4.4 and placed in the within section 5.2 Pharmacokinetics section.

·         Section 4.6 – Minor QRD update

·         Section 4.8 – Addition of the term ‘anaphylaxis’; Updated HPRA details; QRD and minor editorial updates

·         Section 4.9 - Updated statements and management of overdose

·         Section 5.2 – Elderly patients statement removed from section 4.4 and placed within section 5.2

·         Section 6.3 – Editorial update

·         Section 6.5 – Editorial update

·         Section 6.6 – QRD update concerning disposal

·         Section 9 – Minor editorial

·         Section 10 – Date of revision update

 

 

 

 

 

 

 

 

 

 

 

 

Updated on 7 April 2014 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.6 - Special precautions for disposal and other handling

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Changes to:

Section 4.4 - Special warnings and precautions for use,
Section 4.6 - Pregnancy and lactation,
Section 4.7 - Effects on ability to drive and use machines,
Section 4.8 - Undesirable effects,
Section 5.3 - Preclinical safety data,
Section 6.6 - Special precautions for disposal

 

Updated on 4 April 2014 PIL

Reasons for updating

  • Change to side-effects

Updated on 9 September 2013 PIL

Reasons for updating

  • Change to, or new use for medicine
  • Change to warnings or special precautions for use
  • Change to information about pregnancy or lactation
  • Change to information about driving or using machinery

Updated on 19 June 2013 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 5.1 - Pharmacodynamic properties

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Changes to:

Section 4.1 -Therapeutic indications,
Section 5.1 - Pharmacodynamic properties

Updated on 17 September 2012 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

 

4.2       Posology and Method of Administration

 

            Dosage:

 

            Adults (including elderly) and children:

 

            Bactroban Ointment should be applied to the affected area up to three times a day for up to 10 days, depending on the response. Dosage should not exceed ten days.

Updated on 30 August 2011 PIL

Reasons for updating

  • Change due to user-testing of patient information

Updated on 6 May 2010 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.9 - Overdose

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

1.         Name of the Medicinal Product

 

            ‘Bactroban’ 2% w/w Ointment

 

4.3       Contraindications

 

            Hypersensitivity to mupirocin or any of the excipients (see section 6.1).

 

            ‘Bactroban’ ointment should not be given to patients with a history of hypersensitivity to any of its constituents.

 

            This ‘Bactroban’ Ointment formulation is not suitable for ophthalmic or intranasal use.

 

4.4       Special Warnings and Special Precautions for Use

 

            When ‘Bactroban’ Ointment is used on the face, care should be taken to avoid the eyes.

 

            Since absorption of mupirocin from areas of denuded skin has not yet been quantified, it is not recommended that the product be used in patients with skin ulcers, burns or with areas of traumatised skin.

 

            Polyethylene glycol can be absorbed from open wounds and damaged skin and is excreted by the kidneys.  In common with other polyethylene glycol-based ointments, ‘Bactroban’ Ointment should be used with caution if there is evidence of moderate or severe renal impairment.

 

            In the rare event of a possible sensitisation reaction or severe local irritation occurring with the use of ‘Bactroban’ ointment, treatment should be discontinued, the product should be rinsed off and appropriate alternative therapy for the infection instituted.

 

Should a possible sensitisation reaction or severe local irritation occur with the use of Mupirocin Ointment, treatment should be discontinued, the product should be washed off and appropriate therapy instituted.

 

As with other antibacterial products, prolonged use may result in overgrowth of non-susceptible organisms.

 

Renal impairment
Elderly patients: No restrictions unless the condition being treated could lead to absorption of polyethylene glycol and there is evidence of moderate or severe renal impairment.

 

Mupirocin ointment is not suitable for:

-           ophthalmic use

-           intranasal use

-           use in conjunction with cannulae

-           at the site of central venous cannulation.

 

For intranasal use, a separate presentation, Mupirocin nasal ointment, is available.

 

Avoid contact with the eyes. If contaminated, the eyes should be thoroughly irrigated with water until the ointment residues have been removed.

 

Polyethylene glycol can be absorbed from open wounds and damaged skin and is excreted by the kidneys. In common with other polyethylene glycol based ointments, Mupirocin ointment should not be used in conditions where absorption of large quantities of polyethylene glycol is possible, especially if there is evidence of moderate or severe renal impairment.

 

4.5       Interaction with Other Medicinal Products and Other Forms of Interaction

 

            None stated.

 

            No drug interactions have been identified.

 

4.6       Pregnancy and Lactation

 

            This product should not be used during pregnancy and lactation unless considered essential by the physician. 

 

            Pregnancy: Adequate human data on use during pregnancy are not available.  However animal studies have not identified any risk to pregnancy or embryo-foetal development.

           

            Lactation: Adequate human and animal data on use during lactation are not available.

 

Use in pregnancy:

Reproduction studies on mupirocin in animals have revealed no evidence of harm to the foetus. As there is no clinical experience on its use during pregnancy, mupirocin should only be used in pregnancy when the potential benefits outweigh the possible risks of treatment.

 

Use in lactation:

There is no information on the excretion of mupirocin in milk. If a cracked nipple is to be treated, it should be thoroughly washed prior to breast feeding.

 

4.7       Effects on Ability to Drive and Use Machines

 

            None stated.

 

No adverse effects on the ability to drive or operate machinery have been identified.

 

4.9       Overdose

 

            The toxicity of mupirocin is very low.  In the event of overdose accidental ingestion, symptomatic treatment should be given.

 

Updated on 7 April 2009 PIL

Reasons for updating

  • Change to name of manufacturer

Updated on 26 August 2008 SmPC

Reasons for updating

  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 10:
 
should read December 2006

Updated on 9 May 2008 PIL

Reasons for updating

  • Change to name of manufacturer

Updated on 26 April 2007 PIL

Reasons for updating

  • Change of manufacturer

Updated on 9 March 2007 SmPC

Reasons for updating

  • Improved electronic presentation

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 14 December 2006 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 10 August 2004 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 3 July 2003 SmPC

Reasons for updating

  • Improved electronic presentation

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 19 June 2003 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may not be renewed (A)